[go: up one dir, main page]

UA103492C2 - Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) - Google Patents

Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)

Info

Publication number
UA103492C2
UA103492C2 UAA201101400A UAA201101400A UA103492C2 UA 103492 C2 UA103492 C2 UA 103492C2 UA A201101400 A UAA201101400 A UA A201101400A UA A201101400 A UAA201101400 A UA A201101400A UA 103492 C2 UA103492 C2 UA 103492C2
Authority
UA
Ukraine
Prior art keywords
proliferacii
vection
stats
activator
transcription
Prior art date
Application number
UAA201101400A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вальдемар Пребе
Станислав Скора
Тимоти Медден
Изабела Фокт
Чарльз Конрад
Original Assignee
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем filed Critical Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Publication of UA103492C2 publication Critical patent/UA103492C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается пиридинового соединения, эффективного в модуляции активации STAT3 и/или STAT5.Это соединение приемлемо для применения с целью профилактики и лечения пролиферативных заболеваний и состояний, включая рак, воспаления и пролиферативные болезни кожи.
UAA201101400A 2008-07-08 2009-06-26 Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) UA103492C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7900208P 2008-07-08 2008-07-08
PCT/US2009/048782 WO2010005807A2 (en) 2008-07-08 2009-06-26 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)

Publications (1)

Publication Number Publication Date
UA103492C2 true UA103492C2 (ru) 2013-10-25

Family

ID=41507673

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201101400A UA103492C2 (ru) 2008-07-08 2009-06-26 Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)

Country Status (18)

Country Link
US (3) US8143412B2 (ru)
EP (1) EP2307367B1 (ru)
JP (1) JP5675606B2 (ru)
KR (1) KR20110033922A (ru)
CN (1) CN102143947B (ru)
AU (1) AU2009268841B2 (ru)
BR (1) BRPI0915697A2 (ru)
CA (1) CA2729943A1 (ru)
CR (1) CR20110074A (ru)
EA (1) EA020766B1 (ru)
ES (1) ES2521676T3 (ru)
IL (1) IL210423A0 (ru)
MX (1) MX2011000268A (ru)
NZ (1) NZ590372A (ru)
PL (1) PL2307367T3 (ru)
UA (1) UA103492C2 (ru)
WO (1) WO2010005807A2 (ru)
ZA (1) ZA201100536B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101819B1 (en) 2006-11-20 2013-01-09 President and Fellows of Harvard College Methods, compositions, and kits for treating pain and pruritis
EP2307367B1 (en) 2008-07-08 2014-09-24 Board of Regents, The University of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
EP3483273A1 (en) * 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
CN107002037A (zh) * 2014-09-26 2017-08-01 新加坡国立大学 用于调节th‑gm细胞功能的方法和组合物
WO2017024037A1 (en) 2015-08-03 2017-02-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
TWI846678B (zh) * 2017-11-10 2024-07-01 美國德州系統大學評議委員會 咖啡酸衍生物及其用途
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP7630439B2 (ja) 2019-03-11 2025-02-17 ノシオン セラピューティクス，インコーポレイテッド エステル置換イオンチャンネル遮断薬および使用方法
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN113811305A (zh) 2019-03-11 2021-12-17 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20220006139A (ko) 2019-04-05 2022-01-14 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MX2022005335A (es) 2019-11-06 2022-08-17 Nocion Therapeutics Inc Bloqueadores de canales ionicos cargados y metodos de uso.
WO2021183639A1 (en) 2020-03-11 2021-09-16 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL277744A (ru) 1961-05-19
DE2555789A1 (de) 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3410439A1 (de) 1984-03-22 1985-09-26 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-on-2,2-dioxid und dessen nichttoxischen salzen sowie der dabei als zwischenprodukt(e) auftretenden acetoacetamind-n-sulfonsaeure(salze)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
FR2629455B1 (fr) 1988-03-29 1991-09-27 Rhone Poulenc Agrochimie Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
AU662480B2 (en) 1990-04-16 1995-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
JPH05301838A (ja) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
CA2080554A1 (en) 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
CA2092017A1 (en) 1992-03-26 1993-09-27 Tameo Iwasaki Butadiene derivatives and process for preparing the same
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH06247850A (ja) 1993-02-24 1994-09-06 Suntory Ltd １２−リポキシゲナーゼ阻害剤
DE4330105A1 (de) 1993-09-06 1995-03-09 Bayer Ag Verwendung von beta-Hetaryl-beta-oxopropionsäurenitrile als Schädlingsbekämpfungsmittel
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9322781D0 (en) 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406137D0 (en) 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
AU2360595A (en) 1994-04-22 1995-11-16 Hospital For Sick Children Research and Developement Limited Partnership, The Use of benzylidene-malononitrile derivates for the treatment of leukemia
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US20020119129A1 (en) 1997-01-15 2002-08-29 Yeda Research And Development Co. Ltd. Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
DE19707319C1 (de) 1997-02-12 1998-06-18 Mannesmann Ag Verfahren und Einrichtung zum Positionieren der Mündung einer verzehrbaren Lanze
US5854285A (en) 1997-04-03 1998-12-29 Natpro, Inc. Protein kinase inhibitor
US6420338B1 (en) 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CA2298480A1 (en) 1997-07-25 1999-02-04 Tsumura & Co. Pyridylacrylamide derivatives and nephritis remedies and tgf-.beta. inhibitors containing the same
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
KR100674760B1 (ko) 1999-03-04 2007-01-25 리가가쿠 겐큐쇼 촉매 조성물
US20020045191A1 (en) 2000-09-15 2002-04-18 Schneider Robert J. Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
JP2003119169A (ja) 2001-07-30 2003-04-23 Shigetoshi Kadota 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
KR100944174B1 (ko) 2001-11-30 2010-02-24 산텐 세이야꾸 가부시키가이샤 혈관 신생 저해제
AU2003210983A1 (en) 2002-02-11 2003-09-04 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
WO2003073999A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
TW200306195A (en) 2002-04-02 2003-11-16 Tsumura & Co A phosphodiestrase IV inhibitor containing pyridylacrylic acid derivatives
WO2004047743A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
CH696238A5 (de) * 2003-06-30 2007-02-28 Lymphosign Inc Verfahren zur Herstellung von Zimtaldehydverbindungen.
KR20050055479A (ko) 2003-12-08 2005-06-13 김철호 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제
CN102603565A (zh) 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
WO2005092904A1 (en) * 2004-03-26 2005-10-06 Hsc Research And Development Limited Partnership Novel compounds for modulating cell proliferation
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
ES2245887B1 (es) 2004-07-02 2007-04-01 Marcos Serrano Gil Rueda de timon plegable para embarcaciones.
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
BRPI0518030A (pt) 2004-11-22 2008-10-28 Advanced Medical Optics Inc compostos de metino e de antraquinona copolimerizáveis e artigos que os contêm
AU2006212738B2 (en) 2005-02-09 2012-04-05 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
WO2007006143A1 (en) * 2005-07-13 2007-01-18 The Hospital For Sick Children Compositions and methods for detecting transformed cells
CA2641262A1 (en) 2006-02-02 2007-08-16 University Of South Florida Withacnistin compounds for treatment of cancer
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
EP2236620A3 (en) 2006-05-05 2011-05-25 George Mason Intellectual Properties, Inc. Compositions for treating HIV infection
FR2903050B1 (fr) 2006-06-30 2009-02-27 Valeo Systemes Thermiques Dispositif d'eclairage ou de signalisation pour face avant de vehicule automobile et face avant comportant un tel dispositif
US20100292229A1 (en) 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
EP2063882A4 (en) 2006-09-05 2010-03-03 Univ Emory TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS
WO2008083389A1 (en) 2006-12-29 2008-07-10 Moleculin, L.L.C. Methods of treating skin disorders with caffeic acid analogs
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
WO2008121858A1 (en) 2007-03-28 2008-10-09 Board Of Regents, The University Of Texas System Small molecule inhibitors for immune modulation
WO2009009150A2 (en) 2007-07-12 2009-01-15 Renee Michelle Cleary Telecommunication and electronic devices holding apparatus and methods
US8877803B2 (en) 2007-09-10 2014-11-04 Boston Biomedical, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
US7989572B2 (en) 2008-01-17 2011-08-02 Eastman Chemical Company Polyvinyl ultraviolet light absorbers for personal care
EP2307367B1 (en) 2008-07-08 2014-09-24 Board of Regents, The University of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120021941A1 (en) 2009-01-12 2012-01-26 The Board Of Regents Of The University Of Texas System Blood test for the detection of cancer

Also Published As

Publication number Publication date
JP5675606B2 (ja) 2015-02-25
US20140228414A1 (en) 2014-08-14
CN102143947A (zh) 2011-08-03
CA2729943A1 (en) 2010-01-14
US20120149738A1 (en) 2012-06-14
ES2521676T3 (es) 2014-11-13
WO2010005807A2 (en) 2010-01-14
US8637675B2 (en) 2014-01-28
AU2009268841B2 (en) 2014-02-06
EP2307367A4 (en) 2012-04-18
US20110053992A1 (en) 2011-03-03
KR20110033922A (ko) 2011-04-01
JP2011527679A (ja) 2011-11-04
BRPI0915697A2 (pt) 2016-02-10
AU2009268841A1 (en) 2010-01-14
CR20110074A (es) 2011-06-24
CN102143947B (zh) 2015-06-24
US9000179B2 (en) 2015-04-07
EP2307367B1 (en) 2014-09-24
AU2009268841A8 (en) 2011-02-03
MX2011000268A (es) 2011-04-27
EA201170160A1 (ru) 2011-08-30
NZ590372A (en) 2012-09-28
ZA201100536B (en) 2012-06-27
PL2307367T3 (pl) 2015-03-31
EA020766B1 (ru) 2015-01-30
WO2010005807A3 (en) 2010-03-25
IL210423A0 (en) 2011-03-31
US8143412B2 (en) 2012-03-27
EP2307367A2 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
UA103492C2 (ru) Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
SMT201600313B (it) Derivati di solfonammide come agenti che inducono apoptosi selettivi per bcl-2 per il trattamento del cancro e dei disturbi immunitari
MY163004A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
IN2012DN02018A (ru)
TWI367886B (en) Proteasome inhibitors and methods of using the same
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
TW200745109A (en) Pyrrolo-pyridine kinase modulators
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2011006150A (es) Compuestos inhibidores de cinasa.
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
PH12012501389A1 (en) Hedgehog inhibitors
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
NZ598124A (en) Compounds for treatment of inflammation
MX2009010757A (es) Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.